EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Effectiveness of switching to doravirine‐based antiretroviral therapy: A real‐world study in Germany

Christoph Wyen, Michael Sabranski iD, Celia Jonsson-Oldenbüttel, Johannes Bogner, Heribert Knechten, Stefan Esser, Nazifa Qurishi, Sven Schellberg, Irina Kolobova, Jann-Patrick Pelz, Yohance O Whiteside, Bekana K Tadese iD und 1 weitere

HIV Medicine · 2025

DOI: 10.1111/hiv.70061 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift HIV Medicine, 2025. Verfasst von Christoph Wyen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Praxis am Ebertplatz, Cologne, Germany. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Triazoles, Anti-HIV Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Doravirine (DOR)‐based antiretroviral therapy (ART) has been shown in clinical trials to be effective and well tolerated in treating HIV‐1. The EffectiVeness of SwItChing to DORavirine‐based Antiretroviral Therapy (VICDOR) study characterized the use, effectiveness and impact on body weight and lipids of DOR‐based ART in a virologically suppressed switch population using real‐world data from Germany.

Methods

VICDOR was a multicentre, retrospective chart review study of virologically suppressed adults with HIV in Germany who switched to DOR‐based ART between January 2019 and February 2021. Demographic, clinical and laboratory data were collected up to 15 months after the switch.

Results

A total of 193 individuals were included, with a median age of 49 years (range = 21–78), 85.0% were male, 23.8% were obese (BMI ≥30 kg/m 2 ) and 80.8% had at least one comorbidity. Overall, 84.5% switched to DOR/3TC/TDF. The most common reason for switching was to improve tolerability regarding weight gain (37.3%). Of the 161 individuals who remained on DOR and had HIV‐1 RNA results, 99.4% remained virologically suppressed after 12 months (with one individual having ≥50 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPyridonesTriazolesAnti-HIV AgentsDrug SubstitutionHumansMaleFemaleAdultMiddle AgedRetrospective StudiesGermanyAgedYoung AdultHIV-1Weight GainViral LoadTreatment Outcome

Stichwörter der Autor:innen

ARTDORDOR/3TC/TDFHIVantiretroviraldoravirineeffectiveness

Substanzen

PyridonesdoravirineTriazolesAnti-HIV Agents

Autor:innen und Institutionen

  • Praxis am Ebertplatz, Cologne, Germany.
  • First Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
  • ICH Study Center, Hamburg, Germany.
  • MVZ München am Goetheplatz, Munich, Germany.
  • University Hospital Munich, Medizinische Klinik und Poliklinik IV, Munich, Germany.
  • Laboratory Dr. Knechten, Medical Center for HIV and Hepatitis, Aachen, Germany.

ORCID-Profile: Michael Sabranski, Bekana K Tadese

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Zitieren

APA

Wyen, C., Sabranski, M., Jonsson-Oldenbüttel, C., Bogner, J., Knechten, H., Esser, S., Qurishi, N., Schellberg, S., Kolobova, I., Pelz, J. P., Whiteside, Y. O., Tadese, B. K., & Rockstroh, J. K. (2025). Effectiveness of switching to doravirine‐based antiretroviral therapy: A real‐world study in Germany. HIV Medicine. https://doi.org/10.1111/hiv.70061

Vancouver

Wyen C, Sabranski M, Jonsson-Oldenbüttel C, Bogner J, Knechten H, Esser S, et al. Effectiveness of switching to doravirine‐based antiretroviral therapy: A real‐world study in Germany. HIV Medicine. 2025. doi:10.1111/hiv.70061

BibTeX
@article{Wyen2025,
  author = {Wyen, Christoph and Sabranski, Michael and Jonsson-Oldenbüttel, Celia and Bogner, Johannes and Knechten, Heribert and Esser, Stefan and Qurishi, Nazifa and Schellberg, Sven and Kolobova, Irina and Pelz, Jann-Patrick and Whiteside, Yohance O and Tadese, Bekana K and Rockstroh, Jürgen K},
  title = {Effectiveness of switching to doravirine‐based antiretroviral therapy: A real‐world study in Germany},
  journal = {HIV Medicine},
  year = {2025},
  doi = {10.1111/hiv.70061}
}
Kostenlos starten →